Title

37. Psilocybin in the Treatment of Depression: A Meta-Analysis

Faculty Mentor(s)

Dr. Clayton Teem

Campus

Gainesville

Proposal Type

Poster

Subject Area

Psychology

Location

Nesbitt 3110

Start Date

25-3-2022 12:00 PM

End Date

25-3-2022 1:00 PM

Description/Abstract

Background: Depression is among one of the most common mental health disorders in the United States. Though several different treatments exist, not all work effectively for patients. Psilocybin, a serotonin receptor agonist, may be able to provide another route of therapeutic relief for some individuals who suffer from depression.

Methods: Using Dr. Michael Bornstein’s comprehensive meta-analysis software, we were able to compile data from three different studies that administered psilocybin to clinically depressed individuals. The study participants received several levels of treatment and placebo trials. Few viable studies exist due to the legal restriction of psilocybin.

Results: Psilocybin showed a large and significant effect size (Hedges’ g = 1.71 to 2.39) when used in the treatment of depression and depressive symptoms.

Conclusion: These findings suggest that psilocybin may be used as an alternative treatment for depression in some individuals. Further research is needed to understand the true efficacy, effect, and potential benefits of psilocybin for depression and other mental disorders.

Keywords: psilocybin, depression, psychedelics, major depressive disorder, treatment-resistant depression

Media Format

flash_audio

This document is currently not available here.

Share

COinS
 
Mar 25th, 12:00 PM Mar 25th, 1:00 PM

37. Psilocybin in the Treatment of Depression: A Meta-Analysis

Nesbitt 3110

Background: Depression is among one of the most common mental health disorders in the United States. Though several different treatments exist, not all work effectively for patients. Psilocybin, a serotonin receptor agonist, may be able to provide another route of therapeutic relief for some individuals who suffer from depression.

Methods: Using Dr. Michael Bornstein’s comprehensive meta-analysis software, we were able to compile data from three different studies that administered psilocybin to clinically depressed individuals. The study participants received several levels of treatment and placebo trials. Few viable studies exist due to the legal restriction of psilocybin.

Results: Psilocybin showed a large and significant effect size (Hedges’ g = 1.71 to 2.39) when used in the treatment of depression and depressive symptoms.

Conclusion: These findings suggest that psilocybin may be used as an alternative treatment for depression in some individuals. Further research is needed to understand the true efficacy, effect, and potential benefits of psilocybin for depression and other mental disorders.

Keywords: psilocybin, depression, psychedelics, major depressive disorder, treatment-resistant depression